Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
31 March 2017
Question for written answer
to the Commission
Rule 130
Lefteris Christoforou (PPE)

 Subject:  High cost of medicines in Cyprus

The EU Charter of Fundamental Rights recognises the fundamental right to health and healthcare.

Each Member State must ensure universal access for all citizens. We believe that drugs are the key factor of healthcare, where all citizens are entitled to access.

In Cyprus, historically, prices of medicines were at very high levels and, as a result, many citizens could not afford them, particularly vulnerable groups. This, therefore, breached the basic fundamental EU principle for equal access of citizens to healthcare.

I believe that the case of Cyprus needs to be examined by the European Commission to identify the causes of this phenomenon and the increased cost of medicines, and to provide corrective action for the benefit of Cypriot citizens.

The Commission is asked:
1. Is there a relevant report or study on the cost of medicines and the enormous differences between Member States?
2. What will the Commission do to reduce the cost of medicines in Cyprus?
3. How is the right of Cypriot citizens to access to healthcare ensured?
Original language of question: EL 
Last updated: 25 April 2017Legal notice